Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 50Breast Neoplasms 25Neoplasms 6Neoplasm Metastasis 3Prostate Adenocarcinoma 2Breast Neoplasms, Male 2Advanced Breast Cancer 2Recurrence 1Primary Ovarian Insufficiency 1PSA Level Greater Than Two 1Osteitis Deformans 1Lymphatic Metastasis 1Infertility 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Advanced Metastatic Breast Cancer 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hormone Sensitive Prostate Cancer × Goserelin × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡